Effect of once-yearly infusion of zoledronic acid 5 mg on biochemical markers of bone turnover: Data from horizon-PFT

被引：0
|
作者：
Delmas, P. D.
Bauer, D.
Black, D.
Boonen, S. R.
Cosman, F.
Eastell, R.
机构：
[1] Univ Lyon 1, Dept Med, F-69365 Lyon, France
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[3] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[4] Univ Louvain, Ctr Metab Bone Dis, Louvain, Belgium
[5] Helen Hayes Hosp, Dept Med, W Haverstraw, NY USA
[6] No Gen Hosp, Metab Bone Ctr, Sheffield S5 7AU, S Yorkshire, England
来源：
CALCIFIED TISSUE INTERNATIONAL | 2007年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [31] Effect of zoledronic acid (ZOL) 5 mg on fracture risk by age and geographic region in women with postmenopausal osteoporosis: Results from horizon-PFT
    Cauley, J. A.
    Adachi, J.
    Cosman, F.
    Black, D.
    Boonen, S. R.
    Cummings, S.
    Delmas, P.
    Eastell, R.
    BONE, 2007, 40 (06) : S132 - S132
  • [32] The effect of annual treatment with zoledronic acid 5 mg on bone remodeling: Bone histomorphometry results from the HORIZON-PFT.
    Recker, R. R.
    Boonen, S.
    Garcia, P.
    Supronik, J.
    Peichl, P.
    Black, D.
    Krasnow, J.
    Chiodo, I.
    Gasser, J.
    Eriksen, E.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S305 - S306
  • [33] The effect of annual treatment with zoledronic acid 5 mg on bone remodeling: Bone histomorphometry results from the HORIZON-PFT.
    Recker, R. R.
    Boonen, S.
    Garcia, P.
    Supronik, J.
    Peichl, P.
    Black, D.
    Krasnow, J.
    Chiodo, J.
    Gasser, J.
    Eriksens, E.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S290 - S290
  • [34] Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT)
    Jacques, Richard M.
    Boonen, Steven
    Cosman, Felicia
    Reid, Ian R.
    Bauer, Douglas C.
    Black, Dennis M.
    Eastell, Richard
    JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (08) : 1627 - 1634
  • [35] EFFECT OF ONCE-YEARLY ZOLEDRONIC ACID IN MEN AFTER RECENT HIP FRACTURE: RESULTS FROM HORIZON RECURRENT FRACTURE TRIAL
    Boonen, Steven
    Kaufmann, Jean-Marc
    Orwoll, Eric
    Magaziner, Jay
    Colon-Emeric, Cathleen
    Adachi, Rick
    Bucci-Rechtweg, Christina
    Haentjhens, Patrick
    Vanderschueren, Dirk
    Lyles, Kenneth
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 : 180 - 180
  • [36] EFFICACY OF ONCE-YEARLY ZOLEDRONIC ACID 5 MG IN MEN WITH OSTEOPOROSIS WITH DIFFERENT LEVELS OF SERUM TOTAL TESTOSTERONE
    Boonen, Steven
    Reginster, Jean-Yves
    Kaufman, Jean-Marc
    Lippuner, Kurt
    Zanchetta, Jose
    Langdahl, Bente
    Rizzoli, Rene
    Dimai, Hans Peter
    Eriksen, Erik
    Brixen, Kim
    Antunez, Oscar
    Su, Guoqin
    Hruska, Josef
    Vanderschueren, Dirk
    Orwoll, Eric
    OSTEOPOROSIS INTERNATIONAL, 2012, 23 : S79 - S80
  • [37] Three years of treatment with once-yearly zoledronic acid influences the kinetics of bone matrix maturation in osteoporotic patients independent of bone turnover
    Gamsjaeger, S.
    Buchinger, B.
    Gasser, J.
    Eriksen, E. F.
    Klaushofer, K.
    Paschalis, E. P.
    BONE, 2011, 48 : S78 - S79
  • [38] EFFECT OF ONCE-YEARLY IV ZOLEDRONIC ACID IN MEN AFTER HIP FRACTURE: RESULTS FROM THE HORIZON-RECURRENT FRACTURE TRIAL
    Boonen, S.
    Magaziner, J.
    Lyles, K.
    Colon-Emeric, C.
    Adachi, J.
    Bucci-Rechtweg, C.
    Mesenbrink, P.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 84 - 84
  • [39] EFFECT OF ONCE-YEARLY IV ZOLEDRONIC ACID IN MEN AFTER HIP FRACTURE: RESULTS FROM THE HORIZON-RECURRENT FRACTURE TRIAL
    Boonen, S.
    Magaziner, J.
    Lyles, K. W.
    Dennison, E.
    Colon-Emeric, C.
    Adachi, J. D.
    Bucci-Rechtweg, C.
    Mesenbrink, P.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : S271 - S272
  • [40] Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid
    Kasai, Hidefumi
    Mori, Yoko
    Ose, Atsushi
    Shiraki, Masataka
    Tanigawara, Yusuke
    JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (05): : 606 - 613
12345